Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Biotechnology
- Disease
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29375
License Grant
Under a collaboration Agreement with the Company, we retain the right to elect to collaborate in the future development and commercialization of the Company's IL-1 antibody which is in clinical development. Following completion of Phase 2 development and submission to us of a written report on the IL-1 antibody, we have the right, in consideration for an opt-in payment, to elect to co-develop and co-commercialize the IL-1 antibody in North America. Under the collaboration Agreement, the Company has the right to elect to collaborate in the development and commercialization of a second generation IL-1 Trap following completion of its Phase 2 development, should we decide to clinically develop such a second generation product candidate.
Field of Use
Field of Use relates to the medical industry.
IPSCIO Record ID: 1203
License Grant
Under the Agreement, called the IL-1 Antibody Termination Agreement, the parties terminated the 2003 Collaboration Agreement, including the opt-in rights. In exchange for eliminating the Licensee’s right to opt in to the development and commercialization of the Licensor's IL-1 antibody product candidate, the Licensee agreed to pay the Licensor tiered royalties on future aggregate, worldwide annual net sales of certain IL-1 antibody products, including canakinumab (ACZ885), a fully human IL-1 antibody currently under regulatory review to treat cryopyrin-associated periodic syndrome (CAPS).
Field of Use
The rights granted apply to the medical industry.
IPSCIO Record ID: 29300
License Grant
The Licensor announced that it had entered into a royalty Agreement with the Licensee that replaced a previous collaboration and License Agreement for a second-generation interleukin-1 Trap, should the Licensee decide to proceed in the development of this Trap.
License Property
Interleukin-1 (IL-1) is a protein secreted by certain cells in the body. In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system. In excess, it can be harmful and has been shown to be a key driver of inflammation in a variety of diseases.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 6777
License Grant
The parties desire to enter into a definitive agreement to collaborate to produce fully human monoclonal antibodies to certain antigen targets in order to develop and commercialize genomics-derived, antibody-based products on the terms set forth below. The Parties have entered into this collaboration to jointly research, develop and commercialize Collaboration Products with respect to Collaboration Targets throughout the Territory as set forth in this Agreement.
License Property
Collaboration Product shall mean any Antibody Product that contains a Collaboration Antibody.
Field of Use
The rights granted apply for the diagnosis, prophylaxis or treatment of human diseases or conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
